The 3rd U.S. Circuit Court of Appeals ruled that federal law does not preempt state law claims, allowing alleged victims to resume pursuit of their claims.
Fosamax, now owned by Organon, has faced ongoing litigation since 2008, although Merck argued the FDA initially rejected warnings about fractures in 2009, not adding the label until 2011. The litigation involves more than 3,000 pending cases nationwide, centralized in New Jersey, Reuters reported Sept. 20.
The lawsuits have been dismissed and revived twice, with federal courts revisiting the case over preemption, the report said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.